These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 21876444)

  • 1. Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children.
    Best BM; Capparelli EV; Diep H; Rossi SS; Farrell MJ; Williams E; Lee G; van den Anker JN; Rakhmanina N
    J Acquir Immune Defic Syndr; 2011 Dec; 58(4):385-91. PubMed ID: 21876444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir.
    Chokephaibulkit K; Nuntarukchaikul M; Phongsamart W; Wittawatmongkol O; Lapphra K; Vanprapar N; Cressey TR
    J Antimicrob Chemother; 2012 Dec; 67(12):2927-31. PubMed ID: 22923483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children.
    Musiime V; Fillekes Q; Kekitiinwa A; Kendall L; Keishanyu R; Namuddu R; Young N; Opilo W; Lallemant M; Walker AS; Burger D; Gibb DM
    J Acquir Immune Defic Syndr; 2014 Jun; 66(2):148-54. PubMed ID: 24828266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of two generic co-formulations of lopinavir/ritonavir for HIV-infected children: a pilot study of paediatric Lopimune versus the branded product in healthy adult volunteers.
    de Kanter CT; Colbers EP; Fillekes Q; Hoitsma A; Burger DM
    J Antimicrob Chemother; 2010 Mar; 65(3):538-42. PubMed ID: 20056686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults.
    Lamorde M; Byakika-Kibwika P; Boffito M; Nabukeera L; Mayito J; Ogwal-Okeng J; Tjia J; Back D; Khoo S; Ryan M; Merry C
    J Acquir Immune Defic Syndr; 2012 Jul; 60(3):295-8. PubMed ID: 22481601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands.
    Bastiaans DE; Forcat S; Lyall H; Cressey TR; Hansudewechakul R; Kanjanavanit S; Noguera-Julian A; Königs C; Inshaw JR; Chalermpantmetagul S; Saïdi Y; Compagnucci A; Harper LM; Giaquinto C; Colbers AP; Burger DM;
    Pediatr Infect Dis J; 2014 Mar; 33(3):301-5. PubMed ID: 24356253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood.
    Yang J; Nikanjam M; Best BM; Pinto J; Chadwick EG; Daar ES; Havens PL; Rakhmanina N; Capparelli EV
    J Clin Pharmacol; 2018 Dec; 58(12):1604-1617. PubMed ID: 30252146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin.
    Rabie H; Rawizza H; Zuidewind P; Winckler J; Zar H; Van Rie A; Wiesner L; McIlleron H
    J Antimicrob Chemother; 2019 Aug; 74(8):2347-2351. PubMed ID: 31081020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily.
    Ramautarsing RA; van der Lugt J; Gorowara M; Wongsabut J; Khongpetch C; Phanuphak P; Ananworanich J; Lange JM; Burger DM; Ruxrungtham K; Avihingsanon A
    J Acquir Immune Defic Syndr; 2012 Jan; 59(1):55-8. PubMed ID: 22027875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-administration of a commonly used Zimbabwean herbal treatment (African potato) does not alter the pharmacokinetics of lopinavir/ritonavir.
    Gwaza L; Aweeka F; Greenblatt R; Lizak P; Huang L; Guglielmo BJ
    Int J Infect Dis; 2013 Oct; 17(10):e857-61. PubMed ID: 23587599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low dose lopinavir/ritonavir tablet achieves adequate pharmacokinetic parameters in HIV-infected Thai adolescents.
    Klinklom A; Puthanakit T; Gorowara M; Phasomsap C; Kerr S; Sriheara C; Ananworanich J; Burger D; Ruxrungtham K; Pancharoen C
    Antivir Ther; 2012; 17(2):283-9. PubMed ID: 22293065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.
    Puthanakit T; van der Lugt J; Bunupuradah T; Ananworanich J; Gorowara M; Phasomsap C; Jupimai T; Boonrak P; Pancharoen C; Burger D; Ruxrungtham K
    J Antimicrob Chemother; 2009 Nov; 64(5):1080-6. PubMed ID: 19729375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
    van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and 48-week safety and efficacy of generic lopinavir/ritonavir in Thai HIV-infected patients.
    Ramautarsing RA; van der Lugt J; Gorowara M; Sophonphan J; Ananworanich J; Lange JM; Burger DM; Phanuphak P; Ruxthungtham K; Avihingsanon A
    Antivir Ther; 2013; 18(2):249-52. PubMed ID: 22908131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration.
    Rosso R; Di Biagio A; Dentone C; Gattinara GC; Martino AM; Viganò A; Merlo M; Giaquinto C; Rampon O; Bassetti M; Gatti G; Viscoli C
    J Antimicrob Chemother; 2006 Jun; 57(6):1168-71. PubMed ID: 16606636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and virological efficacy after switch to once-daily lopinavir-ritonavir in treatment-experienced HIV-1-infected children.
    Foissac F; Urien S; Hirt D; Frange P; Chaix ML; Treluyer JM; Blanche S
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4320-5. PubMed ID: 21746952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy.
    Cressey TR; Urien S; Capparelli EV; Best BM; Buranabanjasatean S; Limtrakul A; Rawangban B; Sabsanong P; Treluyer JM; Jourdain G; Stek A; Lallemant M; Mirochnick M
    J Antimicrob Chemother; 2015 Jan; 70(1):217-24. PubMed ID: 25261418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.
    Elsherbiny D; Ren Y; McIlleron H; Maartens G; Simonsson US
    Eur J Clin Pharmacol; 2010 Oct; 66(10):1017-23. PubMed ID: 20552180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
    Zhu L; Liao S; Child M; Zhang J; Persson A; Sevinsky H; Eley T; Xu X; Krystal M; Farajallah A; McGrath D; Molina JM; Bertz R
    J Antimicrob Chemother; 2012 Feb; 67(2):465-8. PubMed ID: 22121190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.